First Time Loading...

Organon & Co
NYSE:OGN

Watchlist Manager
Organon & Co Logo
Organon & Co
NYSE:OGN
Watchlist
Price: 18 USD 1.01% Market Closed
Updated: Apr 23, 2024

Intrinsic Value

Organon & Co. is a science based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars a... [ Read More ]

The intrinsic value of one OGN stock under the Base Case scenario is 56.17 USD. Compared to the current market price of 18 USD, Organon & Co is Undervalued by 68%.

Key Points:
OGN Intrinsic Value
Base Case
56.17 USD
Undervaluation 68%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Organon & Co

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling OGN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Organon & Co

Provide an overview of the primary business activities
of Organon & Co.

What unique competitive advantages
does Organon & Co hold over its rivals?

What risks and challenges
does Organon & Co face in the near future?

Has there been any significant insider trading activity
in Organon & Co recently?

Summarize the latest earnings call
of Organon & Co.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Organon & Co.

Provide P/S
for Organon & Co.

Provide P/E
for Organon & Co.

Provide P/OCF
for Organon & Co.

Provide P/FCFE
for Organon & Co.

Provide P/B
for Organon & Co.

Provide EV/S
for Organon & Co.

Provide EV/GP
for Organon & Co.

Provide EV/EBITDA
for Organon & Co.

Provide EV/EBIT
for Organon & Co.

Provide EV/OCF
for Organon & Co.

Provide EV/FCFF
for Organon & Co.

Provide EV/IC
for Organon & Co.

Show me price targets
for Organon & Co made by professional analysts.

What are the Revenue projections
for Organon & Co?

How accurate were the past Revenue estimates
for Organon & Co?

What are the Net Income projections
for Organon & Co?

How accurate were the past Net Income estimates
for Organon & Co?

What are the EPS projections
for Organon & Co?

How accurate were the past EPS estimates
for Organon & Co?

What are the EBIT projections
for Organon & Co?

How accurate were the past EBIT estimates
for Organon & Co?

Compare the revenue forecasts
for Organon & Co with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Organon & Co and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Organon & Co against its competitors.

Analyze the profit margins
(gross, operating, and net) of Organon & Co compared to its peers.

Compare the P/E ratios
of Organon & Co against its peers.

Discuss the investment returns and shareholder value creation
comparing Organon & Co with its peers.

Analyze the financial leverage
of Organon & Co compared to its main competitors.

Show all profitability ratios
for Organon & Co.

Provide ROE
for Organon & Co.

Provide ROA
for Organon & Co.

Provide ROIC
for Organon & Co.

Provide ROCE
for Organon & Co.

Provide Gross Margin
for Organon & Co.

Provide Operating Margin
for Organon & Co.

Provide Net Margin
for Organon & Co.

Provide FCF Margin
for Organon & Co.

Show all solvency ratios
for Organon & Co.

Provide D/E Ratio
for Organon & Co.

Provide D/A Ratio
for Organon & Co.

Provide Interest Coverage Ratio
for Organon & Co.

Provide Altman Z-Score Ratio
for Organon & Co.

Provide Quick Ratio
for Organon & Co.

Provide Current Ratio
for Organon & Co.

Provide Cash Ratio
for Organon & Co.

What is the historical Revenue growth
over the last 5 years for Organon & Co?

What is the historical Net Income growth
over the last 5 years for Organon & Co?

What is the current Free Cash Flow
of Organon & Co?

Discuss the annual earnings per share (EPS)
trend over the past five years for Organon & Co.

Financials

Balance Sheet Decomposition
Organon & Co

Current Assets 4.5B
Cash & Short-Term Investments 693m
Receivables 1.7B
Other Current Assets 2.1B
Non-Current Assets 7.6B
PP&E 1.4B
Intangibles 5.1B
Other Non-Current Assets 1.1B
Current Liabilities 2.9B
Accounts Payable 1.3B
Accrued Liabilities 1.4B
Other Current Liabilities 215m
Non-Current Liabilities 9.2B
Long-Term Debt 8.8B
Other Non-Current Liabilities 459m
Efficiency

Earnings Waterfall
Organon & Co

Revenue
6.3B USD
Cost of Revenue
-2.5B USD
Gross Profit
3.7B USD
Operating Expenses
-2.4B USD
Operating Income
1.3B USD
Other Expenses
-289m USD
Net Income
1B USD

Free Cash Flow Analysis
Organon & Co

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

OGN Profitability Score
Profitability Due Diligence

Organon & Co's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive Operating Income
Positive 3-Year Average ROIC
50/100
Profitability
Score

Organon & Co's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

OGN Solvency Score
Solvency Due Diligence

Organon & Co's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
38/100
Solvency
Score

Organon & Co's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

OGN Price Targets Summary
Organon & Co

Wall Street analysts forecast OGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OGN is 21.93 USD with a low forecast of 15.15 USD and a high forecast of 29.4 USD.

Lowest
Price Target
15.15 USD
16% Downside
Average
Price Target
21.93 USD
22% Upside
Highest
Price Target
29.4 USD
63% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

OGN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

OGN Price
Organon & Co

1M 1M
+1%
6M 6M
+16%
1Y 1Y
-24%
3Y 3Y
-42%
5Y 5Y
-42%
10Y 10Y
-42%
Annual Price Range
18
52w Low
10.95
52w High
24.3
Price Metrics
Average Annual Return -5.62%
Standard Deviation of Annual Returns 1.32%
Max Drawdown -71%
Shares Statistics
Market Capitalization 4.6B USD
Shares Outstanding 256 590 000
Percentage of Shares Shorted 4.88%

OGN Return Decomposition
Main factors of price return

What is price return decomposition?

OGN News

Other Videos

Company Profile

Organon & Co Logo
Organon & Co

Country

United States of America

Industry

Pharmaceuticals

Market Cap

4.6B USD

Dividend Yield

6.29%

Description

Organon & Co. is a science based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company is headquartered in Jersey City, New Jersey and currently employs 9,300 full-time employees. The company went IPO on 2021-05-14. The firm is engaged in developing and delivering health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. Organon has a portfolio of contraception and fertility brands, such as Nexplanon or Implanon NXT, which is a patented long-acting reversible contraceptive. The Company’s Biosimilars portfolio spans across immunology and oncology treatments. The company also has a portfolio of established brands, including brands in cardiovascular, respiratory, dermatology and non-opioid pain management. The firm sells these products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. The company operates approximately six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.

Contact

NEW JERSEY
Jersey City
30 Hudson Street, Fl 33
+15514306000.0
https://www.organon.com/

IPO

2021-05-14

Employees

9 300

Officers

CEO & Director
Mr. Kevin Ali
Executive VP & CFO
Mr. Matthew M. Walsh
Executive VP & Chief Commercial Officer
Ms. Susanne Gabriele Fiedler
Executive VP and Head of Manufacturing & Supply
Mr. Joseph T. Morrissey Jr.
Executive VP & Chief Information Officer
Ms. Rachel A. Stahler
Head of Investor Relations
Ms. Jennifer Halchak
Show More
Executive VP, General Counsel & Corporate Secretary
Mr. Kirke Weaver
Chief Ethics & Compliance Officer
Ms. Susan O'Neal
Chief Communications Officer
Ms. Rebecca Lowell Edwards
Chief Business Development Officer
Mr. Daniel Karp
Show Less

See Also

Discover More
What is the Intrinsic Value of one OGN stock?

The intrinsic value of one OGN stock under the Base Case scenario is 56.17 USD.

Is OGN stock undervalued or overvalued?

Compared to the current market price of 18 USD, Organon & Co is Undervalued by 68%.